Breast cancer trials

AI-generated summary

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer is being studied. Conditions: Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer +4 • Eligibility: * INCLUSION CRITERIA: * Participants with an appropriate HLA match for available Surgery Branch KRAS TCRs with evaluable metastatic solid cancer (e.g., gastrointestinal, genitourinary, breast, ovarian, non-small cell…. Goal: Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc is being studied. Conditions: Breast Cancer Invasive, Prostate Cancer • Eligibility: Pilot Phase Inclusion Criteria: 1. Spanish speakers of Latinx background as defined by the U.S. Census Bureau as anyone from Mexican, Puerto Rican, Cuban, Dominican, Central or South…. Goal: The study aims to develop educational media interventions to prepare Latinx Spanish-speaking radiation oncology patients for a course of breast or prostate cancer radiation therapy and to foster receptivity and informed decision-making around cancer clinical trial participation. Phase/Status/Sponsor: Unknown phase; RECRUITING; Columbia University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Male participants with a histologically documented diagnosis of prostate adenocarcinoma. * Newly diagnosed high-risk and very high-risk (localised/locally advanced) prostate cancer or a high-risk biochemical…. Goal: The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm). Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors is being studied. Conditions: Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult +25 • Eligibility: Inclusion Criteria: \- Must have a pathologically confirmed advanced and unresectable or metastatic solid tumor listed below with documented disease progression on last standard treatment. Part 1 only:…. Goal: The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D). Phase/Status/Sponsor: Unknown phase; RECRUITING; NiKang Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. is being studied. Conditions: Metastatic Solid Tumors, Stage 4 Cancer • Eligibility: Inclusion Criteria: 1. Life expectancy of at least 90 days. 2. Histologically confirmed advanced metastatic solid tumors located between the thoracic inlet and the pelvic floor, that have…. Goal: This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System. Phase/Status/Sponsor: Unknown phase; RECRUITING; New Phase Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Rhomboid Intercostal Sub-serratus Plane Blocks and Erector Spinae Plane Block in Mastectomy Surgeries is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: 1. Breast cancer female patients. 2. ASA class II and III. 3. Age ≥ 18 and ≤ 60 Years. 4. Body mass index (BMI): \> 20…. Goal: Acute post-mastectomy pain can cause adverse impacts on the patients as delayed discharge from post-operative recovery area, impairs pulmonary and immune functions, increases risk of ileus, thromboembolism, myocardial infarction and may lead to increased length of hospital stay. It is also an important factor leading to the development of chronic post mastectomy pain syndrome (PMPS) in almost half of the patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute, Egypt.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is being studied. Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer +27 • Eligibility: Inclusion Criteria: * At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval. * Locally advanced or metastatic solid malignancy…. Goal: The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; PMV Pharmaceuticals, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors is being studied. Conditions: Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland +7 • Eligibility: Inclusion Criteria: This study will look at solid tumors (as a basket trial for any solid cancer) with HER2 positivity based on IHC Procurement Inclusion Criteria 1. The…. Goal: This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cells called HER2 chimeric antigen receptor specific cytotoxic T lymphocytes (HER2 specific CAR T cells), in combination with intra-tumor injection of CAdVEC, an oncolytic adenovirus that is designed to help the immune system including HER2 specific CAR T cell react to the tumor. Phase/Status/Sponsor: Unknown phase; RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Surgery and Radiotherapy in People With Breast Cancer is being studied. Conditions: Metastatic Breast Cancer, HER2-positive Breast Cancer • Eligibility: Inclusion Criteria: * Age ≥ 18 years. * Pathologically-confirmed metastatic breast cancer. * Oligometastatic breast cancer (≤5 discrete metastatic lesions) without CNS involvement; as seen on standard imaging…. Goal: The researchers are doing this study to see if the combination of surgery, locoregional radiation therapy, SBRT (stereotactic body radiation therapy), and the usual approach is more effective in treating oligometastatic HER2-positive breast cancer than the usual approach alone. The researchers will also study the side effects of the study treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PTEN and Organ-Specific microRNAs in Metastatic Breast Cancer is being studied. Conditions: Breast Cancer, Metastatic Breast Cancer, miRNAs +1 • Eligibility: Inclusion Criteria: * Female individuals aged ≥18 years * Ability to provide written informed consent * Group I (Metastatic BC): Histopathologically confirmed breast cancer and radiologically or clinically…. Goal: This prospective observational study aims to evaluate serum levels of PTEN, a tumor suppressor gene, and organ-specific microRNAs (miRNAs) associated with metastatic patterns in breast cancer. Serum samples will be analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR)-based miRNA profiling and enzyme-linked immunosorbent assay (ELISA)-based PTEN quantification. Phase/Status/Sponsor: Unknown phase; RECRUITING; Atlas University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests Sapu003 in adults with advanced mTOR-sensitive solid tumors, in two groups: Cohort A will receive Sapu003 with exemestane for HR+/HER2-negative breast cancer, and Cohort B will receive Sapu003 alone for RCC, NETs, TSC-associated tumors, or HCC. - This is a phase 1b, open-label, dose-escalation study to find the maximum tolerated dose and to assess safety, pharmacokinetics, and any early antitumor activity. - Eligibility includes adults 18 years or older with the specified cancers, ECOG 0–2, and adequate organ function; key exclusions include active brain metastases, uncontrolled infections or other serious conditions, HIV/HBV/HCV infection, recent major surgery, and pregnancy or breastfeeding. - Sapu003 will be given as weekly IV infusions at 5, 7.5, or 10 mg/m2 in 28-day cycles.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors is being studied. Conditions: Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 +14 • Eligibility: Inclusion Criteria: * Histologically confirmed malignancy that is considered surgically incurable with either: * Stage IIIC melanoma including locally relapsed, satellite, in-transit lesions or bulky draining node metastasis…. Goal: This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; Anusha Kalbasi.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors is being studied. Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer +6 • Eligibility: Inclusion Criteria: 1. Adult participants must be 18 years of age or older 2. Advanced or metastatic solid tumors excluding primary central nervous system (CNS) tumors 3. For…. Goal: The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; IDEAYA Biosciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy is being studied. Conditions: Early Stage Breast Carcinoma, Dyspnea • Eligibility: Inclusion Criteria: * Age ≥ 18 years * Within 3 weeks of starting chemotherapy for an early-stage breast cancer diagnosis * Able to exercise independently without needing support…. Goal: This clinical trial studies whether breathing exercises for the muscles that help with breathing air in, inspiratory muscle training (IMT), works to improve breathing muscle strength, shortness of breath, and physical activity levels in women who are receiving chemotherapy for early-stage breast cancer (BC). Cancer and/or treatments for BC can directly result in muscle wasting that involves breathing muscles, skeletal muscles or heart muscles. Phase/Status/Sponsor: Unknown phase; RECRUITING; Ohio State University Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI. is being studied. Conditions: Locally Advanced or Metastatic Breast Cancers • Eligibility: Inclusion Criteria: 1. Women (or men) aged ≥ 18 years on the day of signing the informed consent with histologically proven breast cancer. 2. Metastatic or locally advanced…. Goal: This is a multicenter, prospective, non-randomized, open-label, pharmacokinetic study, aiming to compare the plasma exposure of the payload (free-DXd) in patients treated by T-DXd for locally advanced or metastatic breast cancer according to their BMI. The primary objective is to compare plasma exposition of the payload (free-DXd) between overweight or obese (BMI\>25) and normal weight (BMI≤25) breast cancer patients during the first 3 cycles of Trastuzumab-Deruxtecan (T-DXd). Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut Claudius Regaud.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials is being studied. Conditions: Breast Cancer, NOS, CNS Primary Tumor, NOS, Cervical Cancer, NOS +9 • Eligibility: Inclusion Criteria: Patient must be ≥ 18 years and ≤ 39 years of age at registration. Patient must have a histologically confirmed diagnosis of primary cancer of any…. Goal: The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO. Phase/Status/Sponsor: Unknown phase; RECRUITING; Eastern Cooperative Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers is being studied. Conditions: Pancreatic Cancer, Renal Cell Cancer, Breast Cancer +2 • Eligibility: * INCLUSION CRITERIA: * For Phase I: Evaluable, unresectable cancer expressing CD70 as assessed by immunohistochemistry of resected tissue (greater than or equal to 2+ CD70 positive on…. Goal: Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers is being studied. Conditions: Cancer • Eligibility: Abbreviated Inclusion Criteria: 1. Subject with histological diagnosis of advanced/metastatic cancer \[currently enrolling in CRC only\] 2. Age 18 years or older, is willing and able to provide…. Goal: TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tizona Therapeutics, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast Cancer is being studied. Conditions: Lung Cancer, Breast Cancer • Eligibility: Inclusion Criteria:Sample from adult patients (≥ 18 years) with suspected non-small cell lung cancer or invasive breast cancer or ductal carcinoma in situ. \- Exclusion Criteria: * Samples…. Goal: A multinational observational study to evaluate the current pathology practices and the utilization of computational pathology plus artificial intelligence algorithms in patients with suspected lung and breast cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Collection of Blood From Patients With Cancer is being studied. Conditions: Prostate Cancer, Breast Cancer, Colon Cancer +2 • Eligibility: * INCLUSION CRITERIA: Patients with a known or suspected malignancy and healthy volunteers 18 years of age and older are eligible. Performance status of ECOG 0, 1, 2,…. Goal: This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients is being studied. Conditions: Breast Carcinoma • Eligibility: Inclusion Criteria: 1. Metastatic invasive breast carcinoma of no special type. 2. Females and males of age ≥18 years. 3. Life expectancy \> 3 months. 4. Eastern Cooperative…. Goal: Eclectic is a strategy trial; once the class of treatment (endocrine therapy or chemotherapy) has been allocated according to 16α-18F-fluoro-17β-oestradiol (18F-FES) Positron Emission Tomography/Computed Tomography (PET/CT) results and circulating tumor biomarkers, clinicians will decide which treatment to use. Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut Curie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers is being studied. Conditions: Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Urothelial Cancer +1 • Eligibility: Inclusion Criteria: 1. Patients must have signed a written informed consent form prior to any trial specific procedures; 2. Patients must be ≥18 years old; 3. Histologically confirmed…. Goal: International study that will evaluate the association of prespecified biomarkers with resistance to Antibody-drug conjugates (ADCs), a type of targeted cancer treatment currently used in clinical practice for treating different tumor types. Phase/Status/Sponsor: Unknown phase; RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC is being studied. Conditions: Breast Cancer Stage IV, HER2-low Breast Cancer, Molecular Imaging • Eligibility: Inclusion Criteria: * Female patients age ≥18 years. * Metastatic or locally advanced breast cancer with disease progression after ≥ 1 line of chemotherapy in the palliative setting,…. Goal: This is a prospective, multi-center, open-label, exploratory diagnostic phase II imaging trial for patients with metastatic breast cancer with at least one line of systemic therapy. The overarching aim of the HER2-Ex PET trial is to study the role of precision imaging utilizing positron emission tomography (PET) with the HER2-specific tracer \[68Ga\]Ga-ABY-025 (hereafter referred to as HER2-PET) in enhancing treatment planning for patients with metastatic HER2-expressing breast cancer Patients will be allocated based on HER2-status on PET and biopsy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Renske Altena.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) is being studied. Conditions: Triple-Negative Breast Cancer • Eligibility: Inclusion Criteria: * Has centrally confirmed TNBC, as defined by the most recent American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines * Has no evidence of…. Goal: This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors is being studied. Conditions: Cervical Cancer, Breast Cancer, Colon Cancer +4 • Eligibility: 1. Adult participants (age ≥ 18 years old) with any of the following advanced or metastatic solid tumors (documented history of histologically confirmed diagnosis): 1. Metastatic castration-resistant prostate…. Goal: A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; Orano Med LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI) is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * ECOG 0-2 * Histologically confirmed early-stage HR+HER2- breast cancer documented by biopsy who are prescribed adjuvant abemaciclib * Able to provide written informed consent and…. Goal: This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of their treating providers Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Illinois at Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation +3 • Eligibility: Inclusion Criteria: 1. Provide written informed consent; 2. Advanced solid tumors, difficult to treat or intolerant to standard treatment, suitable for investigational treatment; 3. Has Eastern Cooperative Oncology…. Goal: The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Acerand Therapeutics (Shanghai) Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intravital Microscopy in Human Solid Tumors is being studied. Conditions: Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm +20 • Eligibility: Inclusion Criteria: * Age ≥ 18 years of age * Eastern Cooperative Oncology Group (ECOG)Performance Status of ≤ 2 * Measurable tumor by direct visualization requiring surgical resection…. Goal: This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated with solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Characterization of Extracellular Vesicles in Breast Cancer Patients is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Signing of a specific informed consent for participation to the study * Female sex Population 1: * Diagnosis of early breast cancer; * Indication for…. Goal: Extracellular vesicles (EVs) are lipid bilayer-delimited particles, naturally released from cells and mediators of intercellular cross-talk. In breast cancer (BC), EVs seem to be involved in the tumor microenvironment's shaping, in cancer cells invasion and in the set-up of metastasis. Phase/Status/Sponsor: Unknown phase; RECRUITING; Istituti Clinici Scientifici Maugeri SpA.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients is being studied. Conditions: HER2-positive Breast Cancer • Eligibility: Inclusion Criteria: * Age ≥18 years old. * Newly diagnosed with early or locally advanced HER2 positive breast cancer. * Normal baseline LVEF (˃50%) * Planned to receive…. Goal: Breast cancer can be managed using chemotherapy, endocrine therapy and biological therapy. Treatment is determined and specified according to the characteristics of the tumor including overexpression of the human epidermal growth factor receptor (HER2). Phase/Status/Sponsor: Unknown phase; RECRUITING; Ain Shams University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment is being studied. Conditions: Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms +1 • Eligibility: Inclusion Criteria: * Diagnosis of cancer in either the adjuvant or metastatic setting requiring initial therapy with 5-FU or Capecitabine. * DPYD testing performed by a CLIA-certified laboratory…. Goal: To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and 4) fluoropyrimidine-related toxicities of heterozygous DPYD variant patients assigned to DPYD-guided reduced dosing versus patients with standard dosing in the control arm. Phase/Status/Sponsor: Unknown phase; RECRUITING; Rutgers, The State University of New Jersey.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Palbociclib and Pembrolizumab In Central Nervous System Metastases is being studied. Conditions: Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases • Eligibility: Inclusion Criteria: * Participants must have histologically or cytologically confirmed disease from any solid tumor (Cohort 1) * Participants must have histologically or cytologically confirmed disease from breast…. Goal: This research study is studying This research study is studying the efficacy and safety of the following study drugs as a possible treatment for recurrent central nervous system (CNS) metastases: * Palbociclib alone (Cohort 1) * The combination of palbociclib and pembrolizumab (Cohort 2) Pfizer and Merck, pharmaceutical companies, are supporting this research study by providing the study drugs as well as funding for research activities. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massachusetts General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Strength After Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * ≥18 years of age * Diagnosed with Stage I-III breast cancer, having completed primary cancer treatment (e.g., surgery, chemotherapy, radiation therapy); hormonal therapies and adjuvant…. Goal: The goal of this study is to explore whether a group exercise program called Strength After Breast Cancer can be delivered in an outpatient physical therapy clinic to improve physical function among women after treatment for breast cancer. The main questions this study aims to answer are: * Can the Strength After Breast Cancer program and the associated outcome battery be successfully delivered in an outpatient physical therapy clinic at Massachusetts General Hospital and do participants find the program practical? Phase/Status/Sponsor: Unknown phase; RECRUITING; MGH Institute of Health Professions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE) is being studied. Conditions: Breast Cancer, Breast Cancer Recurrent • Eligibility: Inclusion Criteria: * Age \> 18 years * In-breast recurrence or new primary (ductal carcinoma in situ (DCIS) or invasive carcinoma) * Tumour \<3.0 cm in greatest diameter…. Goal: Breast-conserving surgery followed by re-irradiation with partial breast irradiation (rPBI) has recently been found to be a safe alternative to mastectomy for women who have undergone prior whole breast radiation. By reducing the volume of tissue receiving radiation, rPBI has been associated with less toxicity and improved cosmetic outcomes. Phase/Status/Sponsor: Unknown phase; RECRUITING; University Health Network, Toronto.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing a Mammography Decision Intervention in a Rural Setting is being studied. Conditions: Breast Cancer • Eligibility: Patient Inclusion Criteria: * Females * Aged 39-49 * Upcoming appointment with a participating primary care provider (within 4 weeks) * English or Spanish-speaking Patient Exclusion Criteria: *…. Goal: The overall objective of this COBRE pilot project is to enhance the design of a 3-arm cluster randomized trial that will test the efficacy and mechanism of effect of the MyMammogram DA with or without a provider communication intervention. This will be accomplished through two aims: (1) Refine, with community partner input, a clinical trial protocol to optimize engagement among patients and primary care providers (PCPs) practicing in rural settings. Phase/Status/Sponsor: Unknown phase; RECRUITING; Dartmouth-Hitchcock Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin is being studied. Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer • Eligibility: General inclusion criteria PRE-SCREENING PHASE The following criteria must be met to be eligible to entry into the pre-screening: 1. Patient must be able to sign written pre-screening…. Goal: The multicenter, two-cohort, non-comparative, open-label, phase II clinical trial SABINA aims to analyze the safety and efficacy of MEN1611 in monotherapy and in combination with eribulin, a non-taxane chemotherapy agent, in Hormone Receptor (HR)-known/Human Epidermial Growth Factor Receptor 2 (HER2)-negative, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)/ Phosphatase and Tensin Homolog (PTEN)-altered, unresectable locally advanced or metastatic metaplastic breast carcinoma (MpBC) patients. A run-in phase for safety and tolerability of MEN1611 in combination with standard doses of eribulin will be conducted as an initial step of the cohort A. Phase/Status/Sponsor: Unknown phase; RECRUITING; MedSIR.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a first-in-human, multicenter, open-label Phase 1 trial testing CID-078, an oral Cyclin A/B-RxL inhibitor, for safety, tolerability, and early signs of anti-tumor activity in adults with advanced solid tumors. The study aims to identify a recommended dose for expansion and to compare safety and pharmacokinetics between the original and a new CID-078 formulation, including a test of the effect of food on its absorption. In the dose-expansion part, CID-078 will be studied for anti-tumor activity in three groups: triple-negative breast cancer, small cell lung cancer, and RB1-altered solid tumors, with a possible extra cohort expansion based on the data. Eligible participants include adults with progressed or refractory solid tumors and, in the expansion part, some adolescents aged 12 and older; key exclusions include prior CID-078 exposure, active brain metastases unless treated and stable, interstitial lung disease, significant QT prolongation risk, and certain viral infections or uncontrolled illnesses.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Feasibility, Acceptability and Preliminary Efficacy of the New Iteration of the Innovative Smartphone-based Care Solution for Women With Breast Cancer Undergoing Chemotherapy (iCareBreast+): A Pilot Study Research Proposal is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: Women who: * are the age of 21 years old and above at the point of recruitment; * are diagnosed with stage 1-3 breast cancer; *…. Goal: The overall aim of the study is to evaluate the feasibility, acceptability and preliminary effects of the next iteration of iCareBreast+, an innovative breast care e-support intervention programme, by refining existing contents and building new contents based on comprehensive assessment of breast cancer women's needs and preferences among breast cancer patients undergoing chemotherapy. The specific objectives of this study are: 1. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Centre, Singapore.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Biological Matrices Versus Synthetic Meshes is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: Female age ≥ 18 Women undergoing mastectomy and immediate one-stage mesh assisted implant breast reconstruction as standard treatment Exclusion Criteria: Revision reconstruction surgery Delayed reconstruction surgery. Goal: In this feasibility study, 60 women undergoing reconstruction will be randomly allocated to receive biological or synthetic mesh and followed for 6 months. The findings will tell us if patients and surgeons are comfortable with not being able to choose which mesh is used for the operation. Phase/Status/Sponsor: Unknown phase; RECRUITING; University Hospitals of Derby and Burton NHS Foundation Trust.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of NX-1607 in Adults With Advanced Malignancies is being studied. Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer +11 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 years. * Measurable disease per disease-specific response criteria. * Patients must have disease that is metastatic or unresectable and have received…. Goal: This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nurix Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer is being studied. Conditions: Breast Cancer, Breast Neoplasm, Breast Tumor +1 • Eligibility: Inclusion Criteria: * Must sign study-specific, IRB approved informed consent form prior to study entry. Note consent by legally authorized representative is not allowed for this trial. *…. Goal: The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will prove to be beneficial for women with early stage breast cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Proton Collaborative Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials is being studied. Conditions: Cancer • Eligibility: Inclusion Criteria: * An adult 18 to 100 years of age, * Able to read English or Spanish at least an eighth-grade level, * From a racial/ethnic background…. Goal: The purpose of this study is to pilot test and evaluate an existing tailored ALEX (Agent Leveraging Empathy for eXams) Research Portal to navigate Black and Hispanic adult cancer patients and their family members through referral to cancer clinical trials. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

NO AXILLARY SURGERY IN EARLY BREAST CANCER (OXIGENATE) is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: Older than 18 years old cT1-2 cN0 Negative preoperative assessment of the axilla Breast surgery as first treatment No axillary surgery Multifocal/ multicentric breast cancer Candidates…. Goal: Prospective study will establish a comprehensive international registry specifically for patients who have undergone surgery for primary breast cancer without SLNB. The main objective of this registry is to gather detailed, real-world data on the outcomes of this particular treatment approach, providing insights into the clinical efficacy and quality of life of patients when SLNB is omitted. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Clinica Universidad de Navarra, Universidad de Navarra.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Breast cancEr, FITness and ExeRcise for Heart Health: The BE-FITTER Study is being studied. Conditions: Breast Cancer, Disability Physical, Heart Failure +1 • Eligibility: Inclusion Criteria: * Age ≥60 years * Previously diagnosed with early-stage (I-III) BC * Completed (≥1 year post) primary cardiotoxic treatment (anthracycline-based chemotherapy or trastuzumab-based biological therapy). Exclusion…. Goal: The chemotherapy medications used for breast cancer treatment are important for achieving a cure, but a potential side effect is that they can cause a decline in functional capacity (reduced exercise tolerance and impaired physical function) and increase the risk of cardiovascular disease. The risks of decreased functional capacity and cardiovascular disease are highest in breast cancer survivors as they grow older. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Alberta.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Inspiratory Muscle Training in Obese Breast Cancer Survivors is being studied. Conditions: Cancer Survivors, Obesity, Breast Cancer • Eligibility: Inclusion Criteria: * completed active treatment for a Stage 0-III breast cancer diagnosis within 6 months to 5 years of enrollment. * obese as defined by a body…. Goal: The investigators propose a randomized controlled trial to determine the effectiveness of inspiratory muscle training in improving exercise tolerance among stage 0-III obese breast cancer survivors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Ohio State University Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Sigvotatug Vedotin in Advanced Solid Tumors is being studied. Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms +9 • Eligibility: Inclusion Criteria: * Disease indication * Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on…. Goal: This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. Phase/Status/Sponsor: Unknown phase; RECRUITING; Seagen, a wholly owned subsidiary of Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer is being studied. Conditions: HER2-positive Breast Cancer, Early-stage Breast Cancer • Eligibility: Inclusion Criteria: 1. Signed informed consent must be obtained prior to any trial-specific procedure. Note: Candidate patients in France must be affiliated to a Social Security System (or…. Goal: The primary goal of the DEFINITIVE trial is to demonstrate the effectiveness of the HER2DX diagnostic assay in enhancing the management of patients with early-stage HER2- positive breast cancer. Patients randomized to arm A will receive adjuvant treatment by physician´s choice, blinded to the diagnostic HER2DX test results. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fundacio Clinic Barcelona.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Improving Comprehensive Care of Cancer Patients is being studied. Conditions: Breast Cancer, Gastrointestinal Cancer, Hematologic Cancer • Eligibility: Inclusion Criteria: * For patients: 1) new diagnosis or within three months of treatment initiation for early-stage breast (I-IIIB), GI (Stage I-III), or hematologic (Stage I-III) cancer 2)…. Goal: Cancer survivors have unique healthcare needs, including managing serious late effects, ongoing surveillance, lifestyle modifications to reduce second cancer risk, and psychosocial support. Nearly 70% of survivors have at least one comorbid chronic condition in addition to cancer, which complicates the delivery of quality cancer care. Phase/Status/Sponsor: Unknown phase; RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Optimizing Surgical Decisions in Young Adults With Breast Cancer is being studied. Conditions: Breast Cancer Stage 0, Breast Cancer Stage I, Breast Cancer Stage II +1 • Eligibility: Inclusion Criteria: * Female aged 18-44 * New diagnosis of Stage 0, 1, 2, or 3 unilateral breast cancer * English or Spanish speaking Exclusion Criteria: * Diagnosis…. Goal: The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer. As part of this study, the investigators will evaluate the impact and use a web-based tool called CONSYDER that is designed to provide useful information to young breast cancer patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Weill Medical College of Cornell University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors is being studied. Conditions: Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer +2 • Eligibility: Inclusion Criteria: * Having signed the written Informed Consent Form (ICF); * Male or female aged ≥18 years; * Life expectancy ≥12 weeks; * Eastern Cooperative Oncology Group…. Goal: This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Key Inclusion criteria: * Adult female or male \>= 18 years of age at the time of informed consent * Histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive…. Goal: The purpose of this trial is to estimate the recommended dose (RD) of \[177Lu\]Lu-NeoB in combination with ribociclib and fulvestrant in participants with estrogen receptor (ER) positive (ER+), human epidermal growth factor receptor-2 (HER2) negative (HER2-) and gastrin releasing peptide receptor (GRPR) positive (GRPR+) advanced breast cancer experiencing early relapse from (neo)adjuvant endocrine therapy or who have progressed on endocrine therapy in combination with a CDK4/6 inhibitor for advanced disease. Phase/Status/Sponsor: Unknown phase; RECRUITING; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Beta-only IL-2 ImmunoTherapY Study is being studied. Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma +34 • Eligibility: Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.…. Goal: This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medicenna Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer is being studied. Conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer • Eligibility: Inclusion Criteria: 1. Volunteer to participate in the study, be able to understand the requirements of a clinical study, and willingness to sign a written informed consent form.…. Goal: The goal of this clinical trial is to learn if the investigational drug BL0175 works to treat adult postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative locally advanced or metastatic breast cancer, ovarian cancer and endometrial cancer. It will also learn about the safety of BL0175. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Best-Link Bioscience, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Augmented Reality Feasibility for Non-invasive Preoperative Tracking in Breast Cancer Surgery is being studied. Conditions: Subclinical Breast Cancer Lesion • Eligibility: Inclusion Criteria: * Major women * Requiring conservative surgical management of a subclinical cancerous breast lesion (not palpable), the histology of which has been previously proven by anatomopathology;…. Goal: Breast cancer is diagnosed by imaging at a non-palpable stage in more than half of all cases. Surgical removal requires preoperative guidance. Phase/Status/Sponsor: Unknown phase; RECRUITING; Centre Jean Perrin.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy is being studied. Conditions: Lymphedema, Breast Cancer, Lymphedema • Eligibility: Inclusion Criteria: * Ages 18 to 75 years (inclusive) * Patients undergoing unilateral or bilateral breast cancer related axillary lymphadenectomy * Free of distant metastasis in preoperative screening…. Goal: Lymphedema is a chronic, progressive, and debilitating condition that occurs with disruption or obstruction of the lymphatic system, which commonly occurs a result of breast cancer therapy. The purpose of this study is to determine if the use of a low risk lymphatic reconstruction procedure at the time of axillary lymph node dissection will reduce the risk of developing lymphedema. Phase/Status/Sponsor: Unknown phase; RECRUITING; Stanford University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of LNCB74 in Advanced Solid Tumors is being studied. Conditions: Ovarian Cancer, Breast Cancer, Endometrial Cancer +3 • Eligibility: Inclusion Criteria: 1. The participant provides written informed consent 2. ≥ 18 years of age on day of signing informed consent. 3. Participant with histologically or cytologically confirmed…. Goal: This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; NextCure, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of GC203 TIL in Advanced Malignant Solid Tumors is being studied. Conditions: Solid Tumor, Gynecologic Cancer, Breast Cancer +2 • Eligibility: Inclusion Criteria: * 1\. In the opinion of the Investigator, patients must be able to sign the ICF and complete all study-required procedures. 2\. Patients must be ≥18…. Goal: A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Juncell Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MT-4561 in Patients With Various Advanced Solid Tumors is being studied. Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer +13 • Eligibility: Main Inclusion Criteria: Patients who have failed at least 1 prior therapy and, who have no standard treatment options demonstrated to provide clinical benefit or who are intolerable…. Goal: This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tanabe Pharma America, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases is being studied. Conditions: Breast Cancer, Triple Negative Breast Cancer • Eligibility: Inclusion Criteria: * Provision of signed and dated Informed Consent Form (ICF). * Stated willingness to comply with all study procedures and availability for the duration of the…. Goal: This is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metastases, compared to treatment with Sacituzumab Govitecan alone. Phase/Status/Sponsor: Unknown phase; RECRUITING; H. Lee Moffitt Cancer Center and Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Arm Swelling Occurence in Breast Cancer Patients With Nodal Radiotherapy: Impact of Informing Them of AI-predicted Risk is being studied. Conditions: Unilateral Breast Neoplasms • Eligibility: Inclusion Criteria: 1. Patient must have signed a written informed consent form prior to inclusion visit and to any study specific procedures 2. Women ≥ 18 years 3.…. Goal: Radiotherapy after breast cancer surgery can lead to side effects like arm lymphedema (arm swelling). Lymphedema can cause long-term discomfort and affect quality of life. Phase/Status/Sponsor: Unknown phase; RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Stress Management Intervention Among Breast and Gynecologic Cancer Patients in Viet Nam is being studied. Conditions: Breast Cancer, Gynecologic Cancer • Eligibility: Inclusion Criteria: * Aged 18 years or older * Have a clinician-confirmed diagnosis within the past 12 months of first-time breast and/or gynecologic cancer (e.g., cervical, ovarian, uterine,…. Goal: Psychological distress is common among Vietnamese cancer patients but often underestimated and not detected by professionals due to lack of time and overload of clinical work. Currently no established, evidence-based intervention exists to help address the mental health needs of cancer patients in Viet Nam besides the 'Stronger Together' peer mentoring intervention model that the investigators piloted in 2021-2023. Phase/Status/Sponsor: Unknown phase; RECRUITING; Boston University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries) is being studied. Conditions: Breast Cancer, Breast Cancer Female • Eligibility: Inclusion Criteria: * Age 18 and older female. * Breast ultrasound demonstrating a solid mass that is suspicious for cancer, which would typically undergo either a blind biopsy…. Goal: The purpose of this study is to train Nigerian radiologists to perform ultrasound-guided breast biopsies. Researchers will use mHealth devices to create a sustainable and practical way of training radiologists in Nigeria to perform and clinically implement US-guided breast biopsies into their practice. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dragon Boat Race Versus Family Unsupervised Training to Improve the Physical Function and Quality of Life in Breast Cancer Patients is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Female patients aged 18-75 years; * ECOG performance status of 0-1; * BMI between 18.0 and 30.0; * No prior experience with dragon boat or…. Goal: Investigators plans to conduct a randomized, open, single center clinical study of Dragon Boat Race versus family unsupervised training to improve the physical function and quality of life in breast cancer patients to compare the effects of organized and supervised short-term dragon boat training versus unsupervised home training on body composition, physical function, and quality of life in women after breast cancer surgery. Participants will be assigned to the following intervention protocols at a 1:1 ratio:Dragon Boat Training Group (DB): Conduct 12-week dragon boat training under the guidance of professional coaches.Home-based Unsupervised Training Group (HG): Perform exercises at home independently according to instructional videos for 12 weeks.The primary outcomes are to analyze differences in body composition, physical function, and quality of life.The secondary exploratory outcomes include stratified factors such as menopausal status and surgical methods Phase/Status/Sponsor: Unknown phase; RECRUITING; First Affiliated Hospital of Zhejiang University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ultra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy is being studied. Conditions: Breast Cancer, Proton Therapy • Eligibility: Inclusion Criteria: 1. Age ≥ 40 years 2. Pathologically (cytologically or histologically) confirmed unilateral primary invasive breast carcinoma 3. Breast conserving surgery + sentinel lymph node biopsy/axillary lymph…. Goal: Breast-conserving surgery (BCS) followed by whole-breast irradiation (WBI) remains the standard therapeutic approach for early-stage breast cancer. Long-term follow-up data from the FAST trial (10-year analysis) demonstrated that the 28.5 Gy/5-fraction regimen exhibited comparable adverse effects to the conventional 50 Gy/25-fraction regimen, with no statistically significant differences in photographic cosmetic assessments at 2 and 5 years post-treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Proton and Heavy Ion Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics is being studied. Conditions: Breast Cancer, Colorectal Cancer • Eligibility: Inclusion Criteria: * Any participant over 18 years old who self-identifies as Black or African-American and signs an informed consent form, also referred to as the 'Permission to…. Goal: To identify Black individuals who are eligible for genetic testing through trusted community organizations, and to connect Black individuals and their families to genetic testing and counseling so that they can know their cancer risk and how to decrease it. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Measuring Oncological Value of Exercise and Statin is being studied. Conditions: Prostate Cancer, Breast Cancer, Kidney Cancer +9 • Eligibility: Inclusion Criteria: * The patient has metastatic prostate cancer, breast cancer, ovarian cancer or kidney cancer confirmed histologically and by imaging, for which 1st-line cancer drug treatment is…. Goal: The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tampere University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing is being studied. Conditions: Lung Cancer, Breast Cancer, Gastric Cancer +1 • Eligibility: Inclusion Criteria: 1. 18 to 75 years old, regardless of gender. 2. Score of nutrition risk screening 2002 (NRS2002) is less than 3, NRS20023. 3. Advanced and unresectable…. Goal: To explore the consistency between result of PTC drug screening tests and actual clinical outcome for patients with advanced malignancy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Liu Huang.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer is being studied. Conditions: Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer • Eligibility: Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study…. Goal: This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Ohio State University Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Reproductive Health in Breast Cancer Survivor is being studied. Conditions: Breast Cancer • Eligibility: Exposed cohort (Breast cancer patient) Inclusion Criteria: * Patients aged between 18 and 50 at the time of diagnosis of breast cancer * Diagnosed with stage 1 to…. Goal: With the age of first pregnancy increasing (average age of mother at childbirth: 31.0 in 2022), and the incidence of breast cancer increasing in young women (+2.1% per year according to some registries, more and more women will develop breast cancer before they have a child. FP must be offered to all women under 40 who are going to receive potentially gonadotoxic treatment (French bioethics law of 06/08/04, revised on 07/07/2011). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Institut Cancerologie de l'Ouest.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy is being studied. Conditions: Estrogen Receptor Positive Breast Cancer, Breast Cancer • Eligibility: Inclusion Criteria: 1. be female 2. be 18 years of age or older. 3. have stage I-III ER+ breast cancer 4. be post-menopausal as defined by any of…. Goal: This study is investigating whether breast cancer patients who experience vaginal dryness while on anti-estrogen treatment could benefit from either vaginal estrogen or from a vaginal moisturizer called Replens. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Polly A. Niravath, MD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumors • Eligibility: Inclusion Criteria: * Participants have histologically proven advanced solid tumors with known prevalent and high Ly6E expression, Disease characteristic: Participants should have an unresectable locally advanced or metastatic…. Goal: The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC). Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; EMD Serono Research & Development Institute, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Huaier Granule and Proteinuria is being studied. Conditions: Proteinuria, Breast Cancer Patients • Eligibility: Inclusion Criteria: * \*\*Inclusion Criteria\*\* 1. Female patients aged 18-75 years. 2. Histopathologically confirmed diagnosis of breast cancer. 3. Currently receiving or having a prior history of immunotherapy…. Goal: The goal of this clinical trial is to learn if adding Huaier Granule to standard care can treat proteinuria (excess protein in the urine) in adult female breast cancer patients (aged 18-75) who developed this condition as a side effect of their immunotherapy or anti-angiogenic cancer treatment. The main question it aims to answer is: \* Does the addition of Huaier Granule to standard care improve the effectiveness of proteinuria treatment after 8 weeks? Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Fudan University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib is being studied. Conditions: Ovarian Cancer, Breast Cancer • Eligibility: Inclusion Criteria: 1. Provision of signed and dated, written ICF. 2. Patient is currently deriving clinical benefit, as judged by the Investigator, from continued treatment in an AZ…. Goal: The rationale of the ROSY-O study is to continue to provide study treatment for patients who have participated in a parent study with olaparib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intratumoral N17350 in Advanced Solid Tumors is being studied. Conditions: Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin +4 • Eligibility: Inclusion Criteria: 1. Age ≥18 years (or legal age of consent in the study jurisdiction). 2. Able to provide written informed consent and willing/able to comply with study…. Goal: The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Onchilles Pharma Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Precision Physical Exercise for Personalized Onco-Hematology. is being studied. Conditions: Hematologic Cancer, Colon Cancer, Breast Cancer +3 • Eligibility: Inclusión criteria: * Adult patients (≥18 years), capable of signing the informed consent and willing to participate in the study. * Performance status (ECOG) 0-2. * Specific inclusion…. Goal: Physical exercise, particularly strength training, has become an effective strategy to improve physical function, muscle mass, and quality of life in cancer patients. However, the biological mechanisms underlying these benefits remain poorly understood, especially during active treatment. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University of Salamanca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer is being studied. Conditions: Advanced Breast Cancer • Eligibility: Inclusion Criteria: * Female, age≥18 years old * Expected survival ≥12 weeks * ECOG 0-1 * Pathologically confirmed recurrent or metastatic breast cancer not amenable to curative surgery…. Goal: This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Wenjin Yin.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors is being studied. Conditions: Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC) +6 • Eligibility: Inclusion Criteria: Part A, B, and C: * Written informed consent, dated and signed by the patient prior to any study-specific procedure. * Part B and C are…. Goal: The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of \[68Ga\]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC); Part B: is to determine the recommended phase 2 dose (RP2D) \[maximum tolerated dose (MTD) or lower dose\] for \[177Lu\]Lu-DPI-4452 for each tumor type such as ccRCC, PDAC, CRC, and urothelial carcinoma (UC); Part C: is to evaluate the preliminary antitumor activity of \[177Lu\]Lu-DPI-4452 as monotherapy for each tumor type such as ccRCC, PDAC, CRC, and UC; Part D: is to assess the diagnostic concordance between \[68Ga\]Ga-DPI-4452 Positron Emission Tomography (PET) and the histopathology result of the Indeterminate Renal Mass (IDRM); Part E: is to assess \[68Ga\]Ga-DPI-4452 uptake in each tumour type such as UC, muscle invasive bladder cancer (MIBC), head and neck cancer (H\&N), triple negative breast cancer (TNBC), squamous non-small cell lung cancer (NSCLC), and any other tumor with locally confirmed carbonic anhydrase (CA) IX expression except ccRCC, CRC and PDAC. Phase/Status/Sponsor: Unknown phase; RECRUITING; ITM Oncologics GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA) is being studied. Conditions: Breast Cancer, Locoregional Recurrence, Abemaciclib +1 • Eligibility: Inclusion criteria: 1. The patient has been diagnosed with the first locoregional recurrence (LRR) after receiving definitive treatment for primary breast cancer. LRR includes one or more of…. Goal: The JCOG2313 trial is a multicenter, randomized, phase III study designed to evaluate the efficacy and safety of adjuvant abemaciclib in combination with endocrine therapy versus endocrine therapy alone in patients with hormone receptor (HR)-positive, HER2-negative breast cancer who have undergone curative treatment for their first locoregional recurrence (LRR). Although HR-positive, HER2-negative breast cancer generally has a favorable prognosis, LRR-such as ipsilateral breast tumor recurrence (IBTR), chest wall recurrence, or regional lymph node recurrence-remains a clinically significant event that increases the risk of distant metastasis. Phase/Status/Sponsor: Unknown phase; RECRUITING; Japanese Foundation for Cancer Research.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cryoablation vs Lumpectomy in T1 Breast Cancers is being studied. Conditions: Breast Cancer, Breast Neoplasm • Eligibility: Inclusion Criteria: * Diagnosis of invasive ductal carcinoma of the breast (ER , Her-2 negative) that is grade 1 or 2 with intraductal component \<25%. Must be T1N0M0…. Goal: This trial studies the efficacy and safety of cryoablation in patients with low risk, early stage breast cancer. Cryoablation is a method of killing a tumor by freezing it. Phase/Status/Sponsor: Unknown phase; RECRUITING; Washington University School of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests adding elimusertib (BAY 1895344) to standard chemotherapy with cisplatin, or cisplatin plus gemcitabine, for adults with advanced solid tumors, including urothelial cancer. It is a dose-escalation phase I trial to find the safest and most effective dose and to learn how the combination behaves in the body. The trial will assess safety and tolerability, identify the maximum tolerated dose, and collect pharmacokinetics and early signs of activity, with a focus on urothelial cancer in the triplet arm. Eligible participants are adults 18 or older with measurable advanced disease for which cisplatin-based therapy is suitable; key exclusions include pregnancy, life expectancy under 6 weeks, uncontrolled illness, recent chemotherapy or radiotherapy, and certain drug interactions or prior ATR inhibitors. The study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer is being studied. Conditions: Bone Metastases, HER2-positive Breast Cancer, Liver Metastases +4 • Eligibility: Inclusion Criteria: * Participants must be women who have histological confirmation of metastatic invasive breast cancer that has metastasized outside the region of the primary tumor and axilla;…. Goal: This pilot clinical trial studies how well copper Cu 64-tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET) works in predicting response to treatment with ado-trastuzumab emtansine in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread to other places in the body. Copper Cu 64-DOTA-trastuzumab is a chemotherapy drug (trastuzumab) attached to a radioactive substance. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Well-Being After Breast Cancer Surgery is being studied. Conditions: Coping Skills Training for Persistent Post-Surgical Pain, General Health Education • Eligibility: Inclusion Criteria: * prior diagnosis of Stage 0 to III breast cancer, DCIS or LCiS * received first breast cancer surgery (total or partial mastectomy, lumpectomy) at least…. Goal: The purpose of this study is to compare the benefits of skills training and health education interventions designed specifically to increase the well-being of people with persistent pain after breast surgery for lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), or invasive breast cancer, and to examine the roles of psychological and physiological variables as modifiable contributors to the continuing burden of persistent pain. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Duke University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy is being studied. Conditions: Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Inflammatory Carcinoma +2 • Eligibility: Inclusion Criteria: 1. Is willing and able to provide written informed consent for the trial. 2. Is a female or male and \>/= 18 years of age 3.…. Goal: This phase II trial studies how well pembrolizumab works in treating patients with hormone receptor positive inflammatory breast cancer that has not spread to other parts of the body, who are receiving hormone therapy and did not achieve a pathological complete response to chemotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer is being studied. Conditions: Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast Cancer • Eligibility: Inclusion Criteria: * Patient must have signed a written informed consent prior to any trial specific procedures. (Note : When the patient is physically unable to give his/her…. Goal: This is a phase II, multicentre, open-label, randomised controlled trial (patients are randomly assigned to one treatment arm or the other) evaluating two treatment strategies (sacituzumab govitecan and trastuzumab deruxtecan in an alternative schema or sacituzumab govitecan alone) in patients with locally advanced or metastatic triple-negative breast cancer. The goal is to answer the question: Does alternating sacituzumab goveitecan (SG) and trastuzumab deruxtecan (T-DXd) improve survival in patients with HER2-low metastatic triple-negative breast cancer compared to continuing treatment with SG alone? Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer is being studied. Conditions: TNBC - Triple-Negative Breast Cancer • Eligibility: Inclusion Criteria: 1. Sign the Informed Consent Form (ICF) 2. The patient is judged by the investigator to have the ability to comply with the provisions of the…. Goal: This review will evaluate the efficacy and safety of SHR1210 (Camrelizumab) and antivascular drug(Famitinib) in combination with anthracyclines/taxane-based adjuvant chemotherapy (carrelizumab + FAM + EC-P) compared with conventional chemotherapy regimens (dose-intensive epirubicin and cyclophosphamide, sequential paclitaxel, or EC-P) in patients with early-stage high-risk TNBC. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fudan University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients is being studied. Conditions: Advanced Unresectable or Metastatic Breast Cancer • Eligibility: Inclusion Criteria: 1. Females aged 18-75 years (inclusive); 2. ECOG performance status (PS) score of 0-1; 3. Patients with histopathologically confirmed metastatic or unresectable locally advanced breast cancer,…. Goal: The study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, or HRS-1358 for advanced unresectable or metastatic breast cancer Phase/Status/Sponsor: Unknown phase; RECRUITING; Jiangsu HengRui Medicine Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Stage II-III breast cancer patients, excluding occult breast cancer, inflammatory breast cancer, metaplasia breast cancer * TNBC patients. TNBC was defined as ER \<= 10%,…. Goal: Early triple negative breast cancer patients who do not achieve pathologic complete response after neoadjuvant chemotherapy with or without immunotherapy have bad prognosis. ctDNA effectively identified patients with highest relapse risk. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs. is being studied. Conditions: Metastatic (Stage IV) Melanoma • Eligibility: Inclusion Criteria: In order to participate in the trial, all patients must meet all the following criteria: 1. Patient must have signed the written informed consent prior to…. Goal: Although treatments for breast cancer have improved, 20-30% of patients with early disease develop metastases (cancer that spreads to other parts of the body). Among the different types of breast cancer, hormone-sensitive cancers that do not overexpress the HER2 protein (HR+/HER2-) are the most common. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ADIE-BC - Aligning Dimensions of Interoceptive Experience in Breast Cancer Survivors is being studied. Conditions: Cancer, Primary Breast Cancer • Eligibility: Inclusion Criteria: * 18 years old or older * Residing in the UK and able to travel into London * Can read and write in English * Have…. Goal: A breast cancer diagnosis can lead to significant anxiety, and for many survivors, this anxiety continues well beyond the end of treatment. While standard anxiety therapies are helpful for some, these therapies often fall short for breast cancer survivors due to an individual's unique experience-particularly changes in how survivors perceive and relate to the body, a process known as interoception. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; King's College London.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Olaparib In Metastatic Breast Cancer is being studied. Conditions: Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1) +7 • Eligibility: Inclusion Criteria: * Patients must have histologically confirmed invasive breast cancer with stage IV disease, either biopsy proven or with unequivocal evidence of metastatic disease by physical examination…. Goal: This research study is for patients with metastatic breast cancer. * Metastatic means that the cancer has spread beyond the breast. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Beth Israel Deaconess Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This randomized, controlled, two-center study compares two neuromodulation approaches to improve sleep after radical mastectomy for breast cancer: an ultrasound-guided sympathetic ganglion block (SGB) and a non-invasive transcutaneous auricular vagus nerve stimulation (taVNS). The goal is to see whether taVNS is not worse than SGB for sleep quality after surgery. Sleep will be measured with an actigraphy device and sleep scales within four days post-surgery, with follow-up on sleep disturbances up to 30 days. Eligible participants are adults aged 18-80 who had radical surgery for breast cancer; exclusions include coagulation dysfunction, ear-area infection or trauma, major heart disease or pacemaker, severe neurological or mental illness, allergies to anesthetics, or inability to complete surveys. The trial is not yet recruiting and is sponsored by the Affiliated Hospital of Jiaxing University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer is being studied. Conditions: Metastatic Breast Cancer • Eligibility: Key Inclusion Criteria: * Patients must be at least 18 years of age * Pathologically documented breast cancer that: 1. Is advanced/unresectable (patients that can be treated with…. Goal: DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The LOGIC trial tests whether adding cryoablation, with or without pembrolizumab, improves immune response and tumor control in high-risk, early-stage triple-negative breast cancer. It will enroll women aged 18 to 90 with clinical stage I/II disease and randomize them to three groups: standard neoadjuvant therapy with surgery, cryoablation followed by neoadjuvant therapy and surgery, or cryoablation plus a single dose of pembrolizumab before cryoablation followed by neoadjuvant therapy and surgery. The study will measure immune and tumor changes in blood and tissue (including TILs, T-cell subsets, and cytokines) at multiple time points. Key exclusions include autoimmune disease or chronic immunosuppression, prior immunotherapy, inflammatory breast cancer, pregnancy or breastfeeding, prior radiation, recent vaccination, and other primary cancers or investigational drug use. Status: NOT_YET_RECRUITING.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer is being studied. Conditions: HER2-positive Metastatic Breast Cancer, HER2-positive Advanced Breast Cancer • Eligibility: Inclusion Criteria: * ECOG performance status ≤ 1 * Must have histologically or cytologically confirmed progressive advanced/metastatic HER2-positive breast carcinoma as per the updated American Society of Clinical…. Goal: ZEPHIR-02 is a multicentre, open-label phase II study that will enroll subjects with HER2-positive advanced/metastatic breast cancer (mBC) who have experienced disease progression under trastuzumab deruxtecan (T-DXd) in the metastatic setting. All subjects will undergo baseline biopsy, blood collection, FDG-PET/CT and 89Zr-trastuzumab PET/CT (HER2-PET/CT) and will be classified as HER2-PET/CT positive or negative, as previously described in the ZEPHIR trial. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Jules Bordet Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: 1\) 18-65 Years, female; 2) Histologically documented Triple Negative Breast Cancer (TNBC) patients; 3) Previously untreated non-metastatic (M0) TNBC, T3-4NanyM0 или TanyN+M0 3) Promising radical surgical…. Goal: To explore the application of Camrelizumab with chemotherapy as neoadjuvant treatment of early-stage TNBC. Phase II clinical study of Camrelizumab in neoadjuvant treatment of early-stage TNBC is proposed. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Blokhin's Russian Cancer Research Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of an Online Intervention to Educate Women at High Risk of Breast Cancer on How to Help Reduce Their Risk. is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: 1. Female (whether born female or not) 2. Women aged 40 to 74 years (inclusive) 3. Women who have participated in, or are participating in the…. Goal: Breast cancer remains the most common cancer among women and a major cause of death despite advances in screening and treatment. Current screening programs are not personalized and are experiencing declining participation. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Effect of Health Education Conducted Using Two Different Methods on Women's Knowledge of Breast Cancer, Health Beliefs, Mammography Self-Efficacy, and Participation in Screening Programs is being studied. Conditions: Breast Cancer, Breast - Female • Eligibility: Inclusion Criteria: * Willingness to participate in the study Being a woman aged between 40 and 69 years Being literate Registered at the Family Health Center where the…. Goal: Breast cancer is the most common cancer among women worldwide and can be deadly if not found early. Screening tests like mammograms help find breast cancer early, which improves the chances of successful treatment. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Saglik Bilimleri Universitesi Gulhane Tip Fakultesi.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether adding an ultrasound-guided erector spinae plane (ESP) block before breast cancer surgery improves pain control compared with a placebo/sham block. It is for adults having day-case (ambulatory) breast cancer surgery who are ASA I–III and have BMI under 35 kg/m2. The study aims to find out if the ESP block leads to better postoperative analgesia and a higher quality of recovery in the first 24 hours after surgery, compared with a sham block. Key exclusions include prior ipsilateral breast surgery (other than lumpectomy), chronic opioid use, pregnancy or nursing, inability to provide informed consent or to speak English, and any contraindication to regional anesthesia.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors is being studied. Conditions: Gastric/Gastroesophageal Junction Cancer, Breast Cancer, Colorectal Cancer +3 • Eligibility: Inclusion Criteria: 1. Aged ≥ 18 years (at time of free and informed consent). 2. Participants must have radiographically confirmed progressive disease (PD) during the last treatment prior…. Goal: This is an open-label, multicenter, Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of KJ015 administered subcutaneously in participants with HER2-expressing solid tumors. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Bao Pharmaceuticals Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Implementing Polygenic Risk Scores for Breast Cancer Prevention: a Feasibility Study is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Ability to provide informed consent * Voluntary consent to participate * CanRisk score (without PRS) \> 5% (calculated on www.canrisk.org) * Healthy women with: 1.…. Goal: The goal of this single-arm interventional study is to learn whether integrating a polygenic risk score (PRS) into the CanRisk model can help improve breast cancer risk prediction and prevention in adult women with or without a family history of breast cancer and in women diagnosed with unilateral breast cancer. The main questions it aims to answer are: 1. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Boccia Stefania.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation-induced Toxicity of the Heart is being studied. Conditions: Non-small Cell Lung Cancer, Esophageal Cancer, Breast Cancer Female • Eligibility: Inclusion Criteria: * Patients 18 years old or older * Patient's consent and written consent is available * Patients with the non-small cell lung cancer or esophageal cancer…. Goal: Late side effects in radio(chemo)therapy \[R(CH)T\] pose a critical limitation to patients' overall survival and quality of life. Even though toxicities of the heart are highly relevant for patients with cancer in the thoracic region, risk stratification models for these toxicities are lacking. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Technische Universität Dresden.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Role of Lifestyle Factors in Breast Cancer-Related Outcomes is being studied. Conditions: Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7 +4 • Eligibility: Inclusion Criteria: * Women with stage II or III breast cancer that will be scheduled to undergo a 4 to 6-week course of radiotherapy * Participants must be…. Goal: This randomized clinical trial studies an integrative oncology (making changes in lifestyle and behavior) program in improving cancer-related outcomes in patients with stage II or III breast cancer undergoing radiation therapy. An integrative oncology program consisting of dietary recommendations, physical activity, stress management, social support, and control of environmental contaminants may modify cancer-related biological processes, influence long-term treatment results, and improve the quality of life of patients. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases is being studied. Conditions: Advanced Breast Cancer • Eligibility: Inclusion Criteria: * Female aged ≥18 years at treatment initiation from 2017 - 2023 * Evidence of metastatic breast cancer (MBC) * Documentation of Estrogen/Progesterone receptor-positive (ER/PR+) *…. Goal: Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Brigham and Women's Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC is being studied. Conditions: TNBC - Triple-Negative Breast Cancer, PD-L1 Positive • Eligibility: Inclusion Criteria: 1. Female patients with breast cancer aged \>= 18 years. 2. Based on the pathological report of the latest biopsy or other pathological specimens, the histology…. Goal: This study is aimed to evaluate the efficacy and safety of Sacituzumab Tirumotecan combined with Toripalimab for first-line treatment of PD-L1 positive unresectable Locally Advanced/metastatic triple negative breast cancer (a/mTNBC). Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Tianjin Medical University Cancer Institute and Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Registry Study of Pregnancy and Breast Cancer is being studied. Conditions: Breast Cancer and Pregnancy • Eligibility: Inclusion Criteria: 1. The patient should have signed and dated the informed consent form (ICF). The enrollment of patients who have died is allowed. 2. Women aged ≥…. Goal: An ambispective observational registry study of pregnancy and breast cancer Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Spanish Breast Cancer Research Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Non-contrast DWI for Supplemental Screening is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: 1. Women aged 18 or older 2. Dense breast identified on mammogram Exclusion Criteria: 1. Contra-indication to contrast-enhanced breast MRI (e.g. renal insufficiency with GFR\<60, contrast…. Goal: Diffusion-weighted imaging (DWI) is a short (under 5 minutes) non-contrast MRI technique that has shown promise for the detection and characterization of breast cancer. Our preliminary data has shown that DWI holds potential for detecting mammographically and clinically-occult breast cancers. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Washington.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a patient’s own T cells that are genetically engineered to target mesothelin, given directly into the pleural space to treat malignant pleural disease. - It includes adults with MPD from mesothelioma, metastatic non-small cell lung cancer to the pleura, or breast cancer to the pleura who have already had at least one prior treatment and show mesothelin expression or elevated SMRP. - The study aims to find a safe dose and learn how these CAR T cells affect the cancer and the patient, with an initial dose‑escalation Phase I and a Phase II part that adds pembrolizumab for mesothelioma. - Key exclusions include active CNS metastases, certain autoimmune or cardiac conditions, active infections, pregnancy, and other health issues that could interfere with participation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically proven infiltrating ductal or lobular breast carcinoma * Stage II or III disease * Inflammatory breast cancer allowed * Hormone-receptor status not specified PATIENT…. Goal: RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Histologically confirmed invasive breast cancer. * Hormone receptor-positive (ER positive and/or PgR positive) and HER2-negative disease: ER positive: ≥1% positive cells or Allred score ≥3.…. Goal: This document outlines an investigator-initiated Phase Ib/II clinical trial in Japan, focusing on the combination therapy of ribociclib and anastrozole for patients with hormone receptor-positive (HR-positive), HER2-negative metastatic or recurrent breast cancer. The trial aims to evaluate the efficacy (specifically, overall response rate) and safety of this combination in the Japanese patient population. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Nagoya City University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Comparison of the Breast Tumor Microenvironment is being studied. Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast • Eligibility: Inclusion Criteria: * Female, age greater than or equal to 40 * Core biopsy proven invasive breast carcinoma or ductal carcinoma in situ (DCIS), all subtypes excluding invasive…. Goal: The goal of the project is to identify a molecular signature of tumor stroma from "normal" adjacent breast tissue obtained prospectively at the time of breast conserving surgery before and after receiving intraoperative radiation therapy (IORT) in subjects that have luminal A and triple negative breast cancer. IORT is considered as being standard of care. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Columbia University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests an augmented reality (AR) localization system called SKIA-Breast to guide breast-conserving surgery, comparing it with standard ultrasound-guided skin marking in women with breast cancer. - It is a multicenter randomized study that assigns participants 1:1 to the AR method or the conventional method to see if AR is not worse (non-inferior) to the standard approach. - The main outcome is the rate of negative margins on pathology, with a secondary outcome of how often re-excision is needed for positive margins. - Eligible participants are women aged 19–80 with biopsy-proven breast cancer scheduled for breast-conserving surgery, with tumors 5–30 mm, a single invasive lesion, no metastasis, and the ability to have MRI, CT, and ultrasound. - Key exclusions include pregnancy or breastfeeding, being biologically male, prior neoadjuvant chemotherapy or metastasis, or invasive lobular carcinoma (and any lesions not visible on CT).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Extended Clinical Follow up and Biospecimen Collection for Patients Enrolled in TAILORx and RxPONDER: A Companion Protocol is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Patient must have met the criteria for 1 of the 3 possible cohorts described below: 1. Cohort 1: Previously enrolled on TAILORx (PACCT-1) with recurrence…. Goal: The purpose of this study is to retrieve tissue samples from individuals with breast cancer who previously enrolled on the PACCT-1 (TAILORx) or S1007 (RxPONDER) trials and experiences a recurrence of their cancer (Cohort 1, 2, and 3), and/or the tumor initially removed at surgery in patients previously enrolled in step 1 of S1007 (RxPONDER) and found to have a high Recurrence Score of 26-100 (Cohort 3) but not followed on the study after that point. The tissue will be used for future research designed to understand why breast cancer recurs despite hormonal therapy or chemotherapy plus hormonal therapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Eastern Cooperative Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) is being studied. Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer +13 • Eligibility: Inclusion Criteria: * Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement * For patients enrolled via…. Goal: This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options is being studied. Conditions: Solid Tumors, CNS Tumors • Eligibility: Inclusion Criteria: 1. Disease status: * Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 * Phase 2 portion: * Part…. Goal: This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of Well Being and Patient Reported Outcomes After Robotic Single-port Nipple Sparing Mastectomy and Implant Reconstruction is being studied. Conditions: Breast Reconstruction, Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2) +1 • Eligibility: Inclusion Criteria: * Women aged 18 years and older * Candidates who have already been selected to undergo nipple sparing mastectomy and immediate implant reconstruction by the breast…. Goal: This study is being carried out to better understand how different types of mastectomy surgeries affect women's recovery, satisfaction, and overall well-being after breast cancer surgery and reconstruction. There are different ways to perform a mastectomy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Beaumont Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS) is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * The patients who started treatment with LYNPARZA for the first time for the approved indication "Adjuvant treatment for patients with BRCA-mutated HER2 negative high recurrent…. Goal: To evaluate the frequency of bone marrow suppression Adverse Drug Reactions (ADRs) in patients with BRCA mutated HER2 negative high recurrent risk breast cancer treated with LYNPARZA for adjuvant treatment in the actual post-marketing use. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer is being studied. Conditions: Invasive Breast Carcinoma • Eligibility: Inclusion Criteria: * Age \>= 18 years * Histologically confirmed, operable, invasive breast cancer. Note: Patients with oligometastatic breast cancer (up to 3 isolated distant metastases) will be…. Goal: This early phase I trial evaluates the impact of chemotherapy before surgery (neoadjuvant) on the peripheral blood immune phenotype in patients with operable breast cancer. Collecting blood and information from patients with breast cancer may help to understand how the immune system influences response to treatment, and how the immune system reacts to breast cancer treatment. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer is being studied. Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 +27 • Eligibility: Inclusion Criteria: * FOCUS GROUP: Women seen at the MD Anderson Oncofertility Clinic and Adolescent and Young Adult Program who are 18-45 years old at the time of…. Goal: This study develops infertility survey among reproductive age women with gynecological and breast cancer. This study aims to learn how women consider whether or not to try to have a baby after surviving cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer is being studied. Conditions: Ductal Breast Carcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma +6 • Eligibility: Inclusion Criteria: * Histologically confirmed invasive carcinoma of the breast of any of the following histologies (ductal, lobular, mammary, medullary, or tubular); patients with metaplastic breast cancer are…. Goal: This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Alliance for Clinical Trials in Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: Women who satisfy all of the following conditions will be eligible for this study. 1 DCIS or invasive ductal, medullary, papillary, mucinous (colloid), lobular,or tubular histologies.…. Goal: Stereotactic radiation has been implemented more than 3 decades ago, initially to radiate benign and later malignant tumors within the brain. Doses up to 24 Gy in one session have been used. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Texas Southwestern Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors is being studied. Conditions: Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma +23 • Eligibility: Inclusion Criteria: * Patients must have histologically confirmed, metastatic or unresectable malignancy of the following types: (a) non-small cell lung cancer (NSCLC), (b) triple-negative breast cancer (TNBC; defined…. Goal: This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Piloting 18F-FAPI PET/MRI for Applications in Breast Cancer is being studied. Conditions: Breast Neoplasm Female • Eligibility: Inclusion Criteria: * Inclusion criteria are accepting to undergo 18F-FAPI PET/MRI examinations and 1. diagnosed with local invasive breast cancer, 2. scheduled for neoadjuvant therapy as primary treatment,…. Goal: Breast cancer is the most common type of cancer in Norwegian women, with 4,224 new cases in 2022. More precise diagnosis are expected to result in more accurate assessment of treatment effect, and to contribute to both providing better treatment and reducing overtreatment. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; St. Olavs Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer is being studied. Conditions: Breast Neoplasms • Eligibility: Inclusion Criteria: 1. Adult patients ≥18 years old; 2. Histologically or cytologically confirmed HR+/HER2- (HER2 IHC 0/IHC 1+ or IHC 2+ with FISH-negative) locally advanced unresectable or metastatic…. Goal: The combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy is the standard first-line treatment for advanced HR+ (hormone receptor-positive)/HER2- (human epidermal growth factor receptor 2-negative) breast cancer. However, the optimal treatment strategy after CDK4/6i progression remains unclear. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Yan Xue.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members is being studied. Conditions: Body Mass Index 25 or Greater, BRCA1 Gene Mutation, BRCA2 Gene Mutation +8 • Eligibility: Inclusion Criteria: * PILOTS I, II AND III: Body mass index (BMI) of 25 or higher OR \< 150 minutes of moderate to vigorous exercise per week OR…. Goal: This pilot clinical trial studies different types of energy balance interventions to see how well they work in increasing the physical activity levels of breast cancer gene-positive patients, Lynch syndrome-positive patients, chronic lymphocytic leukemia (CLL) survivors or family members of cancer survivors who are at high risk for cancer. Increasing exercise and eating healthy foods may help reduce the risk of cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer is being studied. Conditions: Breast Neoplasm, Metastatic Breast Cancer, Rb+ Breast Cancer • Eligibility: Inclusion Criteria: 1. At least 18 years of age 2. History of histologically or cytologically confirmed breast cancer, any ER, PR or HER2 status is allowed as long…. Goal: In this study positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer \[18F\]fluorothymidine (FLT). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Pennsylvania.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies is being studied. Conditions: Ovarian Cancer, Breast Cancer, Pancreatic Cancer +10 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 at the time of screening * Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and…. Goal: This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC is being studied. Conditions: Breast Cancer - Female • Eligibility: Inclusion Criteria: 1. Voluntary Participation and Informed Consent: The participant voluntarily agrees to join this clinical trial, signs a written informed consent form, understands the study, and is…. Goal: This prospective, multicenter, single-arm clinical study aims to evaluate the efficacy and safety of AK112 in combination with albumin-bound paclitaxel and carboplatin as neoadjuvant treatment in adult women with early or locally advanced triple-negative breast cancer (TNBC). The study seeks to address the pathological complete response (pCR) rate, objective response rate (ORR), breast conservation rate, and invasive disease-free survival (iDFS) following treatment with AK112 combined with albumin-bound paclitaxel and carboplatin in early or locally advanced TNBC. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shuangyue Liu.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) is being studied. Conditions: Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma +4 • Eligibility: Procurement Inclusion Criteria: 1. Evaluable neuroblastoma with persistent or relapsed disease 1. Recurrent disease following completion of aggressive multi-drug frontline therapy. 2. Progressive disease during aggressive multi-drug frontline…. Goal: This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2. The cancer has either come back after treatment or did not respond to treatment. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * TRIAL SUBJECTS: * Patient age 18 years or older who self-identifies as African-American * In early survivorship phase, defined as being 1-12 months post completion…. Goal: This randomized clinical trial studies peer navigator education in improving survivorship care in African American breast cancer survivors. An educational intervention involving peer groups may help to improve the well-being and quality of life (QOL) in breast cancer survivors Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pharmacogenomics ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms is being studied. Conditions: Breast Cancer • Eligibility: * Select 600 Breast Cancer LCIS Patients who are suitable for breast tissue biopsy * High risk of breast cancer is defined as at least one breast biopsy…. Goal: Explore the relationship between drug target ER gene single nucleotide polymorphisms and Raloxifene therapeutic effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target UGT gene single nucleotide polymorphisms and Raloxifene side-effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Age ≥18 years or older * Histologically confirmed breast adenocarcinoma that is unresectable loco-regionally advanced or metastatic * HER2-positive (immunohistochemistry score 3+) or ERBB2- amplification…. Goal: This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: * Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) * Group B: Trastuzumab + Vinorelbine + Avelumab * Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566) Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Adrienne G. Waks.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Personalized Vaccine for TNBC Immunotherapy is being studied. Conditions: Breast Cancer Female • Eligibility: Inclusion Criteria: 1. Be between 18 and 75 years of age. 2. Histologically confirmed diagnosis of primary triple negative breast carcinoma (TNBC). 3. Patients who have already been…. Goal: Due to their genetic instability, breast tumors that do not express receptors for Estrogens, Progestagens or amplify the Her2 / neu oncogene \[called triple-negative breast cancer (TNBC)\] and other tumors such as melanoma, non-small cell lung cancer, accumulate numerous mutations that make them highly resistant to different regimens of chemo- or radiotherapy, thereby generating high morbidity and mortality. However, immunology can turn the genetic instability of tumors into the Achilles' tendon. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Universidad Nacional de Colombia.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer is being studied. Conditions: Breast Neoplasms • Eligibility: Key Inclusion Criteria: * Participant has adequate tumor tissue for the analysis of PIK3CA mutational status by a Novartis designated laboratory. One new or recent biopsy (collected at…. Goal: The primary objective is to evaluate whether treatment with alpelisib in combination with fulvestrant prolongs Progression Free Survival (PFS) compared to treatment with placebo in combination with fulvestrant. The primary scientific question of interest is: what is the treatment effect based on PFS for alpelisib in combination with fulvestrant versus placebo in combination with fulvestrant in Chinese men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who received prior treatment with an aromatase inhibitor (AI) either as (neo) adjuvant treatment or as treatment for advanced disease, regardless of study treatment discontinuation or start of new anti-neoplastic therapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health is being studied. Conditions: Breast Cancer, Colorectal Cancer, Endometrial Cancer +6 • Eligibility: Inclusion Criteria: * Age 50 years or older * Resident of the continental United States * Diagnosed with multiple myeloma, non-Hodgkin lymphoma, or localized kidney or ovarian cancer;…. Goal: This research study will test the efficacy of interactive, web-based interventions that improve diet, physical activity and weight management changes among early stage survivors of breast, prostate, colorectal, endometrial, renal, thyroid, and ovarian cancers, as well as multiple myeloma and non-Hodgkin Lymphoma. Overarching outcomes also include physical function and performance, muscle mass, quality of life, and health utilities. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Alabama at Birmingham.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) is being studied. Conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer • Eligibility: Inclusion Criteria: * Women who are postmenopausal or premenopausal/perimenopausal * For women who are premenopausal or perimenopausal and for men: willing to undergo and maintain treatment with approved…. Goal: This Phase II, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant compared with physician's choice of endocrine monotherapy in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received one or two prior lines of systemic therapy in the locally advanced or metastatic setting. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC) +2 • Eligibility: Inclusion Criteria: * Phase 1 Dose Escalation cohorts, Phase 1 Backfill cohorts, and Phase 2 Tumor Type-Specific cohort(s): must meet one of the following criteria: * HER2- metastatic…. Goal: NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Nuvation Bio Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) is being studied. Conditions: Breast Cancer, Breast Neoplasms, Colon Cancer +5 • Eligibility: Inclusion Criteria: * Patients will have measurable and/or non-measurable disease, lacking curative options for whom the selected chemotherapy agents represent the standard of care * WHO performance status…. Goal: This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Excision Followed by Radiofrequency Ablation for Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Patient is a female, ≥ 50 years of age * The tumor size is ≤ 3 cm (on pre-study radiologic OR clinical exam) * The…. Goal: The purpose of this study will be to evaluate, in a multi-center setting, the ability of radiofrequency ablation (RFA) of breast cancer lumpectomy sites to extend the "final" negative margin and consequently decrease the rates of re-operation. During the initial breast conservation procedure (lumpectomy), immediately following routine surgical resection of the tumor, radiofrequency energy (RFA) is applied to the wall (bed) of the fresh lumpectomy cavity, thus extending tumor free margin radially beyond the volume of the resected specimen. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Arkansas.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Patients must have histologically and/or cytologically confirmed diagnosis of breast cancer, that is advanced/metastatic or unresectable, for which no curative therapy exists, and be negative…. Goal: The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Canadian Cancer Trials Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Role of Mucosal Associated Invariant t Lymphocytes in Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Female patients admitted at South Egypt cancer institute who diagnosed as breast cancer based on full clinical, radiologic and pathologic assays Exclusion Criteria: 1. Patients…. Goal: Evaluation of MAIT cells in patient recently diagnosed as cancer breast and its correlation with clinical outcome. Mucosal Associated Invariant T cells are a population of unconventional T cells which are enriched in mucosal tissues such as the lung and gut but are also present in other tissues including the skin, adipose tissue and the liver \[4,5,6,7\]. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Assiut University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study is being studied. Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 +14 • Eligibility: Inclusion Criteria: * Breast cancer patients diagnosed with stage 0-IIIA disease who are planned to receive adjuvant hypofractionated or standard fractionated radiation treatment * Patients must have the…. Goal: This clinical trial studies the effect of standard verbal counseling with or without a pictorial educational tool for the reduction of psychological morbidity in patients with stage 0-IIIA breast cancer receiving radiation therapy. Beginning radiation therapy for breast cancer can be stressful. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; OHSU Knight Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Rationale and Trial Design of PFB-03 Study: Diagnostic Performance and Clinical Application of 18F-FAPI-PET/CT for Detecting Axillary Lymph Node Metastasis in Breast Cancer Patients After Neoadjuvant Therapy is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: * Must provide written informed consent * Female at 18-80 years of age * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * With anticipated…. Goal: Axillary lymph node (ALN) status is a crucial prognostic factor in breast cancer. Accurate, non-invasive methods for evaluating axillary lymph node metastasis after neoadjuvant therapy (NAT) are needed to optimize surgical decisions and minimize patient morbidity. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Peking Union Medical College Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Symptom Monitoring Using Patient-Report to Improve Medication Use is being studied. Conditions: Breast Cancer Early Stage Breast Cancer (Stage 1-3), Endocrine Therapy • Eligibility: Inclusion Criteria: * Cisgender women assigned female at birth * Age 18 years or older * Stage 1-3 hormone receptor-positive breast cancer 1. Premenopausal patients being treated with…. Goal: This is an intervention targeting patients at risk for non-adherence to endocrine therapy after primary treatments for hormone-positive breast cancer. In a randomized study, the study team will collect patient-reported symptoms monthly from participants through surveys. Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; Medical College of Wisconsin.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Compassion, Social Support, Flexibility, and Resilience Program for Women Surviving Breast Cancer is being studied. Conditions: Breast Cancer Survivor, Mastectomy • Eligibility: Inclusion Criteria: * Female participants aged between 18 and 65 years. * Participants who have undergone a mastectomy. * Participants who voluntarily agree to participate in the study.…. Goal: The goal of this clinical trial is to investigate the effects of an Acceptance and Commitment Therapy (ACT) based program (ReACT) to increase social support, compassion and psychological flexibility on psychological resilience in women undergoing mastectomy. The main question it aims to answer is: Does the ReACT program improve participants' resilience by increasing social support, compassion, and psychological flexibility? Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; Medipol University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Stereotactic Body Radiation Therapy for Breast Cancer is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: Histologically confirmed diagnosis of invasive breast carcinoma of non-lobular histology. Unifocal tumour Previously assessed by a breast surgeon and medical oncologist, with no surgery being recommended…. Goal: This is a prospective, single institution, phase I-II study of stereotactic body radiotherapy (SBRT) for unresected breast cancer. Twenty-four patients with advanced breast cancer who are not candidates for surgery (metastatic disease, unresectable, medically inoperable) or decline surgery will be enrolled in a prospective study using SBRT (4 fractions of radiation therapy over 12-15 days) as the primary treatment modality. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Toronto Sunnybrook Regional Cancer Centre.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase 1/2 trial testing TC-510, a novel autologous engineered T cell therapy, in adults with advanced cancers that express mesothelin. TC-510 uses T cells modified with a mesothelin-targeting single-domain antibody fused to CD3 and a PD-1:CD28 switch receptor to boost activity against PD-L1–positive cancer cells. Eligible cancers include malignant pleural mesothelioma, serous ovarian adenocarcinoma, pancreatic adenocarcinoma, triple-negative breast cancer, and colorectal cancer, as long as the tumor shows mesothelin expression by immunohistochemistry. Participants must be 18 or older, have 1–5 prior systemic therapies for metastatic or unresectable disease, a good performance status (ECOG 0–1), be fit for leukapheresis, and have adequate organ function; key exclusions are inability to follow study procedures and known non-compliance or drug/alcohol use.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy is being studied. Conditions: Carcinoma Breast • Eligibility: Inclusion Criteria: * Patient has histologically-confirmed carcinoma of breast (all subtypes are permitted) * Patient has undergone mastectomy with tissue expander-based reconstruction and require post-mastectomy radiation therapy (PMRT)…. Goal: The purpose of the study is to evaluate whether a caffeine-based cream can reduce the rates of reconstructive complications in patients with tissue expander based reconstruction requiring post-mastectomy radiation therapy when compared to a placebo cream. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; NYU Langone Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Development and Assessment of the 8-item Chronic Pain Acceptance Questionnaire to Measure Disease Acceptance in Women With Breast Cancer is being studied. Conditions: Breast Cancer, Psychological Adaptation, Psychometrics • Eligibility: Inclusion Criteria: * Adult age * Confirmed histopathological diagnosis of Breast Cancer (BC) * Ability to understand the Italian language Exclusion Criteria: * Documented peripheral or central neurological…. Goal: This observational study was conducted to develop and test a new self-report questionnaire, the Cancer Pathology Acceptance Questionnaire for Breast Cancer (CPAQ-8-BC), specifically adapted for women diagnosed with Breast Cancer (BC). The primary goal is to evaluate if this new tool is a reliable and valid measure for assessing disease acceptance - defined as the psychological ability to acknowledge and experience cancer-related thoughts, emotions, and physical sensations without excessive avoidance or struggle. Phase/Status/Sponsor: Unknown phase; COMPLETED; G. d'Annunzio University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Geriatric Assessment and Promotores (GAP) Pilot Feasibility Study is being studied. Conditions: Breast Cancer, Colorectal Cancer, Prostate Cancer • Eligibility: Inclusion Criteria: 1. Age 65-90 2. Able to understand study procedures and to comply with them for the entire length of the study. 3. Diagnosis of Stage II-III…. Goal: The goal of this clinical trial is to test a new way to help older adults who have had cancer. The researchers want to see if a program that assesses participants health and aging is achievable and makes a difference. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of California, Davis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ) is being studied. Conditions: Radiation Dermatitis, Breast Cancer • Eligibility: Inclusion Criteria: 1. Women with breast cancer, treated with ipsilateral i) Simple (total) mastectomy, OR ii) Modified radical mastectomy, OR iii)Radical mastectomy, OR iv) Segmental mastectomy, OR v)…. Goal: Radiotherapy is a mainstay of treatment in breast cancer treatment, in the adjuvant setting. Radiation dermatitis occurs in up to 65% of these patients; currently, there is no standard of care for this treatment-related toxicity. Phase/Status/Sponsor: Unknown phase; TERMINATED; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tested bemarituzumab in adults whose solid tumors overexpress FGFR2b. - It aimed to assess safety and tolerability and to look for early signs of anti-tumor activity. - Eligible participants had unresectable, locally advanced, or metastatic cancers (such as head and neck squamous cell carcinoma, triple-negative breast cancer, intrahepatic cholangiocarcinoma, lung adenocarcinoma, platinum-resistant ovarian cancer, endometrial or cervical cancer, or other solid tumors) with FGFR2b overexpression and prior therapy. - Exclusions included untreated or symptomatic CNS metastases, certain heart and eye conditions, and prior investigational FGFR pathway inhibitors. - The study status is completed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903 is being studied. Conditions: Ovarian Cancer, Cervical Cancer, Endometrial Cancer +2 • Eligibility: Inclusion Criteria: * Agreement to provide fresh or archived tumor tissue sample within 3 years * Ia (dose escalation phase and dose expansion phase):patients with pathologically confirmed advanced…. Goal: This is an open phase I/Ib clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and initial efficacy of RP903 in patients with advanced malignancies who have failed standard treatment or have no standard treatment options. The study was divided into two parts: dose escalation and dose extension (Phase Ia) and clinical extension (Phase Ib). Phase/Status/Sponsor: Unknown phase; COMPLETED; Risen (Suzhou) Pharma Tech Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

WeCanManage. An mHealth Self-management Tool is being studied. Conditions: Breast Cancer, Head and Neck Cancer, Sarcoma • Eligibility: Inclusion Criteria: Usability Testing of the WeCanManage High Fidelity Prototype * Age 18 or older * Diagnosis of breast cancer, head and neck cancer or sarcoma * Completion…. Goal: Examine the Feasibility, Acceptability, User Satisfaction, and Response Patterns and Preliminary Efficacy on Targeted Patient Reported Outcomes. Using a pre-post, single arm feasibility design with cancer survivors with disabilities Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Illinois at Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Supportive Effects of Craniosacral Therapy for Women With Breast Cancer is being studied. Conditions: Breast Cancer, Complementary Therapies • Eligibility: Inclusion Criteria: * Breast cancer (stage I-III) survivors after finishing curative chemotherapy and/or radiation * Impaired breast caner-related quality of life (\< 112,8 points on the FACT-B) Exclusion…. Goal: Craniosacral Therapy (CST) is a non-manipulative, very gentle, manual treatment method that aims to release restrictions of the fasciae and regulate the arousal of the sympathetic nervous system, which is often increased in chronically ill patients. Initial randomized trials support CST's efficacy and effectiveness in reducing symptoms of patients with psychosomatic and chronic pain disorders. Phase/Status/Sponsor: Unknown phase; COMPLETED; Universität Duisburg-Essen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types is being studied. Conditions: Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer +6 • Eligibility: Inclusion Criteria: * Subjects must have had at least one prior treatment with systemic therapy for advanced and unresectable, or metastatic disease OR is intolerant to, has refused…. Goal: Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Phase/Status/Sponsor: Unknown phase; SUSPENDED; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Nurse-led Mind-body Intervention on Sexual Health for Breast Cancer Survivors is being studied. Conditions: Women's Health: Neoplasm of Breast, Menopause, Premature, Body Image +2 • Eligibility: Inclusion Criteria: * Diagnosed with breast cancer (stages I - III) between ages 18 - 50 * Completed active treatment (chemotherapy and/or radiation) within the last five years…. Goal: The goal of this clinical trial is to test the efficacy of a nurse-led psychoeducational sexual health intervention for young women breast cancer survivors. The main questions it aims to answer are: 1. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Arkansas.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients is being studied. Conditions: Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma +14 • Eligibility: Inclusion Criteria: \- Exclusion Criteria: \-. Goal: AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Phase/Status/Sponsor: Unknown phase; AVAILABLE; AVM Biotechnology Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of [225Ac]-FPI-1434 Injection is being studied. Conditions: Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer +7 • Eligibility: Inclusion Criteria: 1. Pathologically documented, definitively diagnosed, advanced solid tumour that is refractory to all standard treatment, for which no standard treatment is available, or it is contraindicated,…. Goal: This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of \[225Ac\]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of \[225Ac\]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent). Phase/Status/Sponsor: Unknown phase; TERMINATED; Fusion Pharmaceuticals Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.